CP-690550A - CAS 1243290-37-0
Catalog number:
1243290-37-0
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C15H21N5O2
Molecular Weight:
303.37
COA:
Inquire
Targets:
JAK
Description:
This active molecular is a novel Janus Kinase 3 (JAK3) inhibitor. CP-690550A is an immunosuppressant for the treatment of rheumatoid arthritis, psoriasis, transplant rejection and other immune-mediated disorders.
Publictions citing BOC Sciences Products
  • >> More
Purity:
98%
Appearance:
Powder
Synonyms:
UNII-Q7ZOK859UK; Tofacitinib metabolite M2; Q7ZOK859UK; CHEMBL1630791; 2-hydroxy-1-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]ethanone
Solubility:
Soluble in DMSO
Storage:
-20°C Freezer
MSDS:
Inquire
Application:
immune-mediated disorders
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
InChIKey:
CCOHWQFOFWCBMH-PWSUYJOCSA-N
InChI:
InChI=1S/C15H21N5O2/c1-10-4-6-20(13(22)8-21)7-12(10)19(2)15-11-3-5-16-14(11)17-9-18-15/h3,5,9-10,12,21H,4,6-8H2,1-2H3,(H,16,17,18)/t10-,12+/m1/s1
Canonical SMILES:
CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CO
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related JAK Products


CAS 937272-79-2 Pacritinib

Pacritinib
(CAS: 937272-79-2)

Pacritinib, also known as SB1518, is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic acti...

CAS 1092939-17-7 Ruxolitinib phosphate

Ruxolitinib phosphate
(CAS: 1092939-17-7)

Ruxolitinib phosphate is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus J...

CAS 202475-60-3 JANEX-1

JANEX-1
(CAS: 202475-60-3)

A cell-permeable, reversible, potent, ATP-competitive, and specific inhibitor of JAK3 (Janus family kinase 3; IC50 = 78 µM). Has no effect on JAK1, JAK2, or Zap...

CAS 1092499-93-8 NVP-BSK805

NVP-BSK805
(CAS: 1092499-93-8)

NVP-BSK805, a quinoxaline derivative, is a selective ATP-competitive JAK2 inhibitor which could induce apoptosis (GI50 < 100 nM) and restrain the growth of JAK2...

CAS 540737-29-9 Tofacitinib Citrate

Tofacitinib Citrate
(CAS: 540737-29-9)

Tofacitinib (trade name Xeljanz, formerly tasocitinib, CP-690550) is a drug discovered and developed by Pfizer. It is currently approved for the treatment of rh...

CAS 1056636-06-6 CYT387 sulfate salt

CYT387 sulfate salt
(CAS: 1056636-06-6)

CYT387 sulfate is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3.

CAS 916742-11-5 R-932348

R-932348
(CAS: 916742-11-5)

A dual JAK/SYK inhibitor that can be used to treat diseases and disorders of the eye.

CAS 1229236-86-5 LY2784544

LY2784544
(CAS: 1229236-86-5)

Gandotinib is a potent and selective JAK inhibitor, which effectively inhibited JAK2V617F-driven signaling and cell proliferation in Ba/F3 cells (IC50=20 and 55...

CAS 1092939-16-6 Ruxolitinib sulfate

Ruxolitinib sulfate
(CAS: 1092939-16-6)

Ruxolitinib sulfate (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1...

CAS 945755-56-6 XL019

XL019
(CAS: 945755-56-6)

CAS 477600-75-2 Tofacitinib

Tofacitinib
(CAS: 477600-75-2)

Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.It is currently approved f...

CAS 1056636-07-7 CYT387 Mesylate

CYT387 Mesylate
(CAS: 1056636-07-7)

CYT387 Mesylate is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3.

CAS 1640292-55-2 Oclacitinib Maleate

Oclacitinib Maleate
(CAS: 1640292-55-2)

Oclacitinib, also called as PF-03394197, is a novel inhibitor of JAK family members (IC50= 10 - 99 nM) and JAK1-dependent cytokines involved in allergy, inflamm...

NS-018
(CAS: 1239358-86-1)

NS-018, a selective JAK2 as well as Src family tyrosine kinases inhibitor that could probably induce the apoptosis of tumor cells. It is still under Phase I/II ...

Itacitinib
(CAS: 1334298-90-6)

Itacitinib is a potent Janus kinase-1 inhibitor under the development of AstraZeneca and Incyte Corporation. Itacitinib can inhibit OCT2-mediated uptake of crea...

CAS 211555-05-4 WHI-P97

WHI-P97
(CAS: 211555-05-4)

WHI-P97 is a potent cell-permeable and specific inhibitor of JAK3(IC50 = 11 μM). Inhibits JAK3 in immune complex kinase assaysin a dose-dependent fashion and re...

CAS 195371-52-9 NSC 42834

NSC 42834
(CAS: 195371-52-9)

A cell-permeable pyridinylbutanone compound that inhibits cellular autophosphorylation of both the wild-type Jak2 and the constitutively active V167F mutant (IC...

CAS 1206161-97-8 Filgotinib

Filgotinib
(CAS: 1206161-97-8)

Filgotinib, also known as GLPG0634, is a potent and selective JAK1 inhibitor. Filgotinib displayed a selectivity of 30-fold for JAK1- over JAK2-dependent signal...

CAS 273727-89-2 ZM 39923

ZM 39923
(CAS: 273727-89-2)

ZM 39923 inhibits Janus kinase (IC50=10 nM).

Quick Inquiry

Verification code

Featured Items